How we treat chronic graft-versus-host disease.

Link to article at PubMed

Related Articles

How we treat chronic graft-versus-host disease.

Blood. 2014 Nov 14;

Authors: Flowers ME, Martin PJ

Chronic graft-versus-host disease (GVHD) remains a common and potentially life-threatening complication of allogeneic hematopoietic stem cell transplantation (HCT). The 2-year cumulative incidence of chronic GVHD requiring systemic treatment is approximately 30-40% by NIH criteria. The risk of chronic GVHD is higher and the duration of treatment is longer after HCT with mobilized blood cells than with marrow cells. Clinical manifestations can impair activities of daily living and often linger for years. Hematology and oncology specialists who refer patients to centers for HCT are often subsequently involved in the management of chronic GVHD when patients return to their care after HCT. Treatment of these patients can be optimized under shared care arrangements that enable referring physicians to manage long-term administration of immunosuppressive medications and supportive care with guidance from transplant center experts. Keys to successful collaborative management include early recognition in making the diagnosis of chronic GVHD, comprehensive evaluation at the onset and periodically during the course of the disease, prompt institution of systemic and topical treatment, appropriate monitoring of the response, calibration of treatment intensity over time in order to avoid over- or under-treatment, and the use of supportive care to prevent complications and disability.

PMID: 25398933 [PubMed - as supplied by publisher]

Leave a Reply

Your email address will not be published.